China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
WALTHAM, Mass., March 02, 2016 -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class pharmaceuticals to address the medical needs of patients with kidney and vascular diseases, announced today that Company management will present at the Cowen and Company 36th Annual Health Care Conference in Boston on Tuesday, March 8, 2016, at 8:40 am ET.
About Proteon Therapeutics
Proteon Therapeutics is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon’s lead product candidate, vonapanitase (formerly PRT-201), is an investigational drug intended to improve arteriovenous fistula (AVF) patency, the period of time during which an AVF remains open with adequate blood flow to enable hemodialysis. Proteon is currently evaluating vonapanitase in two Phase 3 clinical trials in patients with chronic kidney disease (CKD) undergoing surgical creation of a radiocephalic AVF for hemodialysis and has completed a Phase 1 clinical trial in patients with symptomatic peripheral artery disease (PAD). For more information, please visit www.proteontherapeutics.com.
Investor Contact
George Eldridge, Senior Vice President and Chief Financial Officer
781-890-0102
[email protected]
Press Contact
Chris Erdman, MacDougall Biomedical Communications
781-235-3060
[email protected]
